In today’s biopharma landscape, microbial versatility isn’t a luxury—it’s a necessity. For decades, Escherichia coli has been the microbial workhorse of the CDMO world, offering fast growth, simple genetics, and ease of scale-up. But the biologics being made today—complex enzymes, glycosylated proteins, biosimilars, and new modalities—are pushing the limits of what E. coli can deliver. […]
